CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Trial StartPositive
AI Analysis

Summary

Stoke Therapeutics announced that its Dravet syndrome trial has exceeded enrollment targets with zero patient dropouts, indicating strong trial execution and patient retention.

Clinical Trial Data

Importance:4/10
Sentiment:
0.60
clinical trialenrollmentDravet syndromepositive progress
Related Companies

Read the original article

Published by yahoo_finance on August 18, 2026 12:01 AM

Read Original